EUVIMEDOpdag EUVIMED
Crossref

Long‐term cost‐effectiveness analysis of tirzepatide versus semaglutide 1.0 mg for the management of type 2 diabetes in the United States

William J Valentine, Meredith Hoog, Reema Mody iD, Mark Belger, Richard Pollock iD

Diabetes, Obesity and Metabolism · 2023

DOI: 10.1111/dom.14979 ↗

At a glance

Journal article in Diabetes, Obesity and Metabolism, 2023. Written by William J Valentine and 4 co-authors. Institution: Ossian Health Economics and Communications GmbH, Basel, Switzerland. Major MEDLINE topics: Diabetes Mellitus, Type 2. Cited 29 times so far (Crossref); 35 references. Funded by: Eli Lilly and Company.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Aim

To evaluate the long‐term cost‐effectiveness of tirzepatide (5, 10 and 15 mg doses), a novel glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) receptor agonist, versus semaglutide 1.0 mg, an injectable glucagon‐like peptide‐1 receptor agonist, based on the results of the head‐to‐head SURPASS‐2 trial, from a US healthcare payer perspective. Materials and Methods The PRIME Type 2 Diabetes Model was used to make projections of clinical and cost outcomes over a 50‐year time horizon. Baseline cohort characteristics, treatment effects and adverse event rates were derived from the 40‐week SURPASS‐2 trial. Intensification to insulin therapy occurred when HbA1c reached 7.5%, in line with American Diabetes Association recommendations. Direct costs in 2021 US dollars (US$) and health state utilities were derived from published sources. Future costs and clinical benefits were discounted at 3% annually.

Results

All three doses of tirzepatide were associated with lower diabetes‐related complication rates, improved life expectancy, improved quality‐adjusted life expectancy and higher direct costs versus semaglutide. This resulted in incremental cost‐effectiveness ratios of US$ 75 803, 58 908 and 48 785 per quality‐adjusted life year gained for tirzepatide 5, 10 and 15 mg, respectively, versus semaglutide. Tirzepatide remained cost‐effective versus semaglutide over a range of sensitivity analyses.

Conclusions

Long‐term projections based on the SURPASS‐2 trial results indicate that 5, 10 and 15 mg doses of tirzepatide are likely to be cost‐effective versus semaglutide 1.0 mg for the treatment of type 2 diabetes in the United States.

Subjects

MeSH terms (MEDLINE)

Diabetes Mellitus, Type 2HumansUnited StatesHypoglycemic AgentsCost-Effectiveness AnalysisCost-Benefit AnalysisTirzepatideSemaglutide

Author keywords

United Statescost-effectivenessmodellingsemaglutidetirzepatide

Substances

Hypoglycemic AgentsTirzepatideSemaglutide

Authors and institutions

  • Ossian Health Economics and Communications GmbH, Basel, Switzerland.
  • Eli Lilly and Company, Indianapolis, Indiana, USA.
  • Eli Lilly and Company Ltd, Bracknell, UK.
  • Covalence Research Ltd, London, UK.

ORCID profiles: Reema Mody, Richard Pollock

Funding

  • Eli Lilly and Company

Cite

APA

Valentine, W. J., Hoog, M., Mody, R., Belger, M., & Pollock, R. (2023). Long‐term cost‐effectiveness analysis of tirzepatide versus semaglutide 1.0 mg for the management of type 2 diabetes in the United States. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.14979

Vancouver

Valentine WJ, Hoog M, Mody R, Belger M, Pollock R. Long‐term cost‐effectiveness analysis of tirzepatide versus semaglutide 1.0 mg for the management of type 2 diabetes in the United States. Diabetes, Obesity and Metabolism. 2023. doi:10.1111/dom.14979

BibTeX
@article{Valentine2023,
  author = {Valentine, William J and Hoog, Meredith and Mody, Reema and Belger, Mark and Pollock, Richard},
  title = {Long‐term cost‐effectiveness analysis of tirzepatide versus semaglutide 1.0 mg for the management of type 2 diabetes in the United States},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2023},
  doi = {10.1111/dom.14979}
}
Start for free →